# Extension Study of Etelcalcetide for Treatment of Secondary Hyperparathyroidism in Patients With Chronic Kidney Disease on Hemodialysis

> **NCT02102204** · PHASE3 · COMPLETED · sponsor: **Amgen** · enrollment: 902 (actual)

## Conditions studied

- Hyperparathyroidism, Secondary

## Interventions

- **DRUG:** Etelcalcetide

## Key facts

- **NCT ID:** NCT02102204
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-03-25
- **Primary completion:** 2016-11-04
- **Final completion:** 2017-06-26
- **Target enrollment:** 902 (ACTUAL)
- **Last updated:** 2017-11-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02102204

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02102204, "Extension Study of Etelcalcetide for Treatment of Secondary Hyperparathyroidism in Patients With Chronic Kidney Disease on Hemodialysis". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02102204. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*